fashion -WSS

fashion

author：explore 2025-09-30 16:25:00 - browse：18588

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： A Greenpeace activist is fined for crash

knowledge

WSS

Cosmetics set for new safety regulation. Why the industry is on board

One Duchenne patient's bittersweet hope for new treatment

Women's World Cup brings attention to abuse in soccer

In early work, researchers turn to CRISPR to treat Alzheimer's

In early work, researchers turn to CRISPR to treat Alzheimer's

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

hotspot

fashion

knowledge

What does generative AI mean for health care? We asked experts

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

As demand for Covid shots wanes, Moderna seeks its next success

In early work, researchers turn to CRISPR to treat Alzheimer's

Medicare details structure of new drug price negotiation program

Why hospitals are withdrawing from US News rankings

At least 13 dead in Texas as scorching temps continue

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

In age of alternative facts, a scholarly course on calling out crap

One Duchenne patient's bittersweet hope for new treatment

knowledge

Watch the official trailer for 'Ahsoka' series

Antibody drugs appear effective. Now can we make enough of them?

Companies helping big Covid

In early work, researchers turn to CRISPR to treat Alzheimer's

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

entertainment

knowledge

knowledge

entertainment